Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisks (NYSE:NVO) Ozempic for reducing the risk of kidney ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

The safety committee of the European Medicines Agency (EMA) will again study the medication, semaglutide, out of concerns ...

Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again ...

Beach huts worth £40k in Milford-on-Sea are brutally washed away as Storm Herminia batters Britain.

Results from a study of a higher dose of Wegovy disappointed investors and European drug regulators ... after concerns it could be linked to Ozempic. With list prices of about $1,000 a month ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...